Identification And Molecular Characterisation Of High-risk Premalignant Breast Lesions
Funder
National Health and Medical Research Council
Funding Amount
$560,382.00
Summary
Understanding the full repertoire of genetic events that underlie the development of breast cancer may allow development of prevention strategies. This study will analyse genetic data of benign breast lesions that may be non-obligate precursors of breast cancer. Importantly, clinical management of these lesions is difficult. A reliable method of predicting the risk of progression to cancer would be a significant advance, with benefits to individual patients and also the health system.
Personalising Care In Operable Pancreas Cancer. GAP-T: A Study Of Imaging And Molecular Biomarkers To Guide Treatment Of Patients Receiving Preoperative Chemotherapy Followed By Surgery.
Funder
National Health and Medical Research Council
Funding Amount
$405,345.00
Summary
We are studying ways to improve how we treat patients with pancreatic cancer. We will use a novel imaging tool, the PET scanner, to show where active cancer is and how quickly and how well a new drug combination (gemcitabine and nab-paclitaxel) is affecting the cancer. We will also study if measuring the expression of specific proteins (SPARC and hENT1) in the cancer affects the outcome and will allow us to determine ahead of time which patients will benefit most from the drugs.
Forecasting The Impact Of Climate Change On Dengue Transmission
Funder
National Health and Medical Research Council
Funding Amount
$506,432.00
Summary
Dengue fever (DF) is the most important mosquito-transmitted viral disease in the world. The large-scale re-emergence of DF in the Asia-Pacific region during the past few decades has renewed its status as a serious international public health problem. Global climate change is anticipated to impact upon the biology and ecology of vectors and consequently the risk of DF transmission. The principal research aim of this study is to project the impact of future climate change on DF.
Understanding Sensitivity And Resistance To Trastuzumab And Lapatinib In HER2 Overexpressing Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$414,056.00
Summary
Previously, women diagnosed with a breast cancer that overexpressed the HER2 protein had a very high risk of dying. Trastuzumab, a treatment targeted at this protein, has been an extremely effective treatment. Currently there are new anti-HER2 drugs available, which will likely to be used in combination with trastuzumab. We will be investigating biological markers of resistance and sensitivity to these drugs and combinations in order to try and understand who needs which drug and/ or combination ....Previously, women diagnosed with a breast cancer that overexpressed the HER2 protein had a very high risk of dying. Trastuzumab, a treatment targeted at this protein, has been an extremely effective treatment. Currently there are new anti-HER2 drugs available, which will likely to be used in combination with trastuzumab. We will be investigating biological markers of resistance and sensitivity to these drugs and combinations in order to try and understand who needs which drug and/ or combinations.Read moreRead less